Wall Street brokerages predict that ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) will post ($0.59) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for ACADIA Pharmaceuticals’ earnings. The highest EPS estimate is ($0.55) and the lowest is ($0.64). ACADIA Pharmaceuticals posted earnings of ($0.65) per share in the same quarter last year, which would suggest a positive year over year growth rate of 9.2%. The firm is expected to issue its next earnings results on Tuesday, February 27th.

On average, analysts expect that ACADIA Pharmaceuticals will report full-year earnings of ($2.42) per share for the current year, with EPS estimates ranging from ($2.47) to ($2.37). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.62) per share, with EPS estimates ranging from ($1.92) to ($1.38). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that follow ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.10. The business had revenue of $35.58 million during the quarter, compared to analyst estimates of $32.03 million. ACADIA Pharmaceuticals had a negative net margin of 320.71% and a negative return on equity of 67.68%. ACADIA Pharmaceuticals’s revenue for the quarter was up 571.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.61) earnings per share.

A number of analysts recently weighed in on the stock. Zacks Investment Research raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a report on Wednesday, November 15th. ValuEngine lowered shares of ACADIA Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of ACADIA Pharmaceuticals in a report on Wednesday, November 8th. Cowen reissued a “buy” rating and issued a $46.00 price target on shares of ACADIA Pharmaceuticals in a report on Tuesday, November 7th. Finally, Jefferies Group reissued a “buy” rating and issued a $47.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, October 12th. One analyst has rated the stock with a sell rating, four have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $47.44.

Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) opened at $30.16 on Friday. ACADIA Pharmaceuticals has a fifty-two week low of $24.31 and a fifty-two week high of $41.20.

In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 37,500 shares of the firm’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $40.91, for a total value of $1,534,125.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 22.25% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the business. San Francisco Sentry Investment Group CA bought a new position in ACADIA Pharmaceuticals in the second quarter valued at approximately $125,000. Turner Investments LLC bought a new position in ACADIA Pharmaceuticals in the third quarter valued at approximately $188,000. Oppenheimer Asset Management Inc. boosted its stake in ACADIA Pharmaceuticals by 10.0% in the second quarter. Oppenheimer Asset Management Inc. now owns 5,133 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 468 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in ACADIA Pharmaceuticals by 43.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,670 shares of the biopharmaceutical company’s stock valued at $214,000 after acquiring an additional 1,710 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. boosted its stake in ACADIA Pharmaceuticals by 56.8% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,509 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 2,358 shares during the last quarter. 93.49% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Brokerages Anticipate ACADIA Pharmaceuticals Inc. (ACAD) to Post -$0.59 EPS” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/02/brokerages-anticipate-acadia-pharmaceuticals-inc-acad-to-post-0-59-eps.html.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Get a free copy of the Zacks research report on ACADIA Pharmaceuticals (ACAD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Stock Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.